IMRB - Mondor Biomedical Research InstituteRémy

TRAjectoires of Cognitive decline and Recovery (TRACER)

Contacts

Head Philippe Remy

Tél.: 01 49 81 36 93
cmYubXJlc25pQHltZXIuZXBwaWxpaHA=

The TRACeR (TRAjectories of Cognitive decline and Recovery – TRACeR) team, INSERM U955, is a joint research unit involving INSERM, UPEC, and the École Normale Supérieure, which evolved from the Interventional Neuropsychology (NPI) team. It is led by Professor Philippe Remy.

TRACeR is based at two complementary sites: the Mondor Institute for Biomedical Research (UPEC School of Medicine, Créteil) and the Department of Cognitive Studies at the École Normale Supérieure (Paris), where basic research, clinical research, and artificial intelligence are closely integrated.

Scientific Identity and Mission

TRACeR is developing an interdisciplinary and multimodal approach to neurocognitive disorders (e.g., Huntington’s disease, Parkinson’s disease, Alzheimer’s disease, Lewy body dementia, and stroke), integrating three complementary dimensions: fundamental cognitive neuroscience, clinical research in patients, and digital technologies and artificial intelligence.

The team’s ambition is twofold: to understand cognitive trajectories, from decline to functional recovery, and to influence these trajectories by developing monitoring tools and innovative therapeutic interventions.

Research axes :

1. Multimodal biomarkers: TRACeR develops assessment and monitoring tools based on the integration of heterogeneous data: voice analysis, brain imaging (MRI, PET), biological biomarkers (plasma, genomic), and clinical and environmental data. This convergence of modalities enables detailed, longitudinal characterization of patients, providing a better understanding of the heterogeneity of clinical profiles.

2. Artificial Intelligence and Digital Health: Artificial intelligence research is a core focus of TRACeR, conducted collaboratively across both sites. The team is developing machine learning methods to detect cognitive decline early, model progression and recovery trajectories, automate voice and image analysis, and deploy remote cognitive assessment tools. This work contributes to the development of precision medicine in cognitive neurology.

3. Therapeutic Interventions and Cognitive Restoration: Building on the founding concept of interventional neuropsychology, TRACeR investigates the potential for cognitive restoration following intervention: cell and gene therapies, neuromodulation, and rehabilitation. The team designs and evaluates these approaches within the framework of national and international multicenter clinical trials, placing cognitive assessment at the heart of the evaluation of therapeutic efficacy.

4. Clinical Pathways and Real-World Impact: TRACeR aims to integrate its tools into actual care pathways: at-home cognitive monitoring, continuous monitoring, and medical decision support. The goal is to reduce disparities in access to specialized assessment and improve the quality of life for patients and their caregivers, beyond the confines of clinical trials.

Technological development and transfer:

Technological development is at the heart of TRACeR’s strategy. The team actively develops industrial partnerships, pharmaceutical collaborations, and technology transfer projects (licensing, creation of spin-offs). It leverages its membership in national clinical and translational networks (National Reference Center for Huntington’s Disease, Parkinson’s Disease Expert Center, NS-PARK/F-CRIN, NeurATRIS) and international networks (Enroll-HD, European HD Network, ERN-RND, RHLF) to deploy its innovations on a large scale and promote their adoption in clinical practice.

Keywords:

Cognition · Language · Voice analysis · Artificial intelligence · Brain imaging · Multimodality · Biomarkers · Neurocognitive disorders · Huntington’s disease · Parkinson’s disease · Stroke · Cognitive trajectories · Therapeutic interventions · Remote monitoring · Technology transfer · Clinical trials

Selected publications

Le Moine C, Fraisse S, Lunven M, Fabre A, Youssov K, Morgado G, Titeux H, Le Ludec T, Goizet C, Fougeron C, Massart R, Bachoud-Lévi AC. A deep learning model for speech-based prediction of clinical scores in people with Huntington’s disease: a longitudinal study with cross-sectional replication.
Lancet Digital health. In press

Gil-Salcedo A, Massart R, Youssov K, Morgado G, Bachoud-Lévi AC. Profiles of patients at early stages of Huntington's disease based on routine biological markers and disease progression.

Journal of Neurology. 2026;273(4):249. doi:10.1007/s00415-026-13717-0

Gil-Salcedo A, Lunven M, Jacquemot C, Massart R, Bachoud-Lévi AC. Specific contribution of cognitive and motor impairments with functional capacity and dependence in Huntington's disease.

Journal of Neurology. 2025;272(3):224. doi:10.1007/s00415-025-12982-9

Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, Anheim M, Maltête D, Remy P, Eggert K, Pape H, Geny C, Couratier P, Carroll C, Sheridan R, Burn D, Pavese N, Raw J, Berg D, Suchowersky O, Kalia LV, Evans A, Drapier S, Danaila T, Schnitzler A, Corvol JC, Defer G, Toiber Temin N, Fradette C, Tricta F, Moreau C. Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.

Journal of Parkinson's Disease. 2025;15(1):72–86. doi:10.1177/1877718X241300295

Chenain L, Riad R, Fraisse N, Jubin C, Morgado G, Youssov K, Lunven M, Bachoud-Lévi AC. Graph methods to infer spatial disturbances: Application to Huntington's disease speech.

Cortex. 2024;176:144–160. doi:10.1016/j.cortex.2024.04.014

Meissner WG, Remy P, Giordana C, Maltête D, Derkinderen P, Houéto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, Carrière N, Catala H, Colin O, Corvol JC, Damier P, Dellapina E, Devos D, Drapier S, Fabbri M, Ferrier V, Foubert-Samier A, Frismand-Kryloff S, Georget A, Germain C, Grimaldi S, Hardy C, Hopes L, Krystkowiak P, Laurens B, Lefaucheur R, Mariani LL, Marques A, Marse C, Ory-Magne F, Rigalleau V, Salhi H, Saubion A, Stott SRW, Thalamas C, Thiriez C, Tir M, Wyse RK, Benard A, Rascol O; LIXIPARK Study Group. Trial of Lixisenatide in Early Parkinson's Disease.

New England Journal of Medicine. 2024;390(13):1176–1185. doi:10.1056/NEJMoa2312323

Lunven M, Hernandez Dominguez K, Youssov K, Hamet Bagnou J, Fliss R, Vandendriessche H, Bapst B, Morgado G, Remy P, Schubert R, Reilmann R, Busse M, Craufurd D, Massart R, Rosser A, Bachoud-Lévi AC. A new approach to digitized cognitive monitoring: validity of the SelfCog in Huntington's disease.

Brain Communications. 2023;5(2):fcad071. doi:10.1093/braincomms/fcad071

Lemercier P, Cléret de Langavant L, Hamet Bagnou J, Youssov K, Lemoine L, Audureau E, Massart R, Bachoud-Lévi AC. Self-Reported Social Relationship Capacities Predict Motor, Functional and Cognitive Decline in Huntington's Disease.

Journal of Personalized Medicine. 2022;12(2):174. doi:10.3390/jpm12020174

Nguyen QTR, Ortigoza Escobar JD, Burgunder JM, Mariotti C, Saft C, Hjermind LE, Youssov K, Landwehrmeyer GB, Bachoud-Lévi AC. Combining Literature Review With a Ground Truth Approach for Diagnosing Huntington's Disease Phenocopy.

Frontiers in Neurology. 2022;13:817753. doi:10.3389/fneur.2022.817753

Bachoud-Lévi AC, Massart R, Rosser A. Cell therapy in Huntington's disease: Taking stock of past studies to move the field forward.

Stem Cells. 2021;39(2):144–155. doi:10.1002/stem.3300

Bachoud-Lévi AC, Ferreira J, Massart R, Youssov K, Rosser A, Busse M, Craufurd D, Reilmann R, De Michele G, Rae D, Squitieri F, Seppi K, Perrine C, Scherer-Gagou C, Audrey O, Verny C, Burgunder JM. International Guidelines for the Treatment of Huntington's Disease.

Front Neurol. 2019 Jul 3;10:710. doi: 10.3389/fneur.2019.00710. eCollection 2019.